Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.60 |
| ▸ | PGK2 | P07205 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585265 | 0.98 | PGK1 (0.58) | PGK1PGK2CYP1A2CYSLTR1CYSLTR2 | |
| SCHEMBL1585270 | 0.98 | PGK1 (0.58) | PGK1PGK2CYP1A2CYSLTR1CYSLTR2 | |
| SCHEMBL27765219 | 0.81 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2ALDH1A1GAA | |
| SCHEMBL1585267 | 0.80 | CYP1A2 (0.45) | CYP1A2CYSLTR1CYSLTR2ALDH1A1GAA | |
| SCHEMBL28322707 | 0.79 | ALDH1A1 (0.53) | CYP1A2CYSLTR1CYSLTR2ALDH1A1GAA | |
| SCHEMBL9005990 | 0.77 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2ALDH1A1GPBAR1 | |
| SCHEMBL8183037 | 0.77 | PGK1 (0.50) | PGK1PGK2 | |
| SCHEMBL10374296 | 0.76 | PDE10A (0.58) | PGK1PGK2CYP1A2ALDH1A1GAA | |
| SCHEMBL2401081 | 0.75 | CYP1A2 (0.44) | CYP1A2CYSLTR1CYSLTR2ALDH1A1GAA | |
| SCHEMBL29426992 | 0.75 | CYP1A2 (0.44) | CYP1A2CYSLTR1CYSLTR2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | PGK1 1401/4885PGK2 616/4885CYP1A2 629/4885 |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | PGK1 1613/4885PGK2 1758/4885CYP1A2 4027/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | PGK1 1351/4885PGK2 1512/4885CYP1A2 634/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PGK1 1335/4885PGK2 1472/4885CYP1A2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.